In the weeks leading up to Donald Trump repeatedly telling pregnant Americans “don’t take” Tylenol, administration officials were pushing the president to focus his announcement on a little-known generic drug as a potential therapy for some people with autism.
That all changed after Health Secretary Robert F. Kennedy Jr. met with Tylenol’s CEO.